Alessandra Ida Celia retweeted
🔬 Exciting news in #Lupus! Our latest study is out. Discover how urinary biomarkers can transform lupus nephritis diagnosis & guide treatment. Plus novel insights into disease mechanism 🚀🚀. Dive into the research here buff.ly/48JqcGg #Rheumatology #Nephrology
Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis: buff.ly/48JqcGg
@andreafava @HopkinsMedicine
#Nephrology
Alessandra Ida Celia retweeted
✅ The latest KDIGO guidelines for the management of #lupus #nephritis have just been published ⬇️ This is THE reference for anyone interested in the management of #LN 👍
KDIGO is pleased to announce the publication of the 2024 Clinical Practice Guideline for the Management of Lupus Nephritis, published today in the January 2024 issue of Supplement to Kidney International, with an Executive Summary published in the main pages of the journal.
Read the news release: kdigo.co/2024-Lupus-Nephriti…
Read the guideline in Kidney International: kdigo.co/2024-Lupus-Nephriti…
Download the guideline: kdigo.co/2024-Lupus-Nephriti…
Developed under the stewardship of Co-Chairs Brad Rovin, MD (US) and Jürgen Floege, MD (DE), this guideline is an update of the Lupus Nephritis (LN) chapter of the KDIGO 2021 Glomerular Diseases Guideline.
"We are thrilled to publish the Lupus Nephritis Guideline, which follows only two years after the publication of the KDIGO Glomerular Diseases Guideline and reflects the latest advancements in the field,” said Dr. Rovin. "This guideline offers critical insights into navigating the complexities of LN treatment, especially with the introduction of novel therapies, and highlights the need for individualized therapy selection based on patient-specific factors and clinical scenarios. With ongoing trials evaluating additional novel therapeutics and promising new data on the horizon, the guideline sets the stage for future advancements in the management and treatment of LN.”
"This guideline includes several key updates to inform clinical decision-making, leveraging the latest evidence to integrate new treatments into the arsenal of established clinical standards,” said Dr. Floege. “A section on chronic kidney disease progression in LN underscores the importance of addressing broader kidney health concerns beyond acute treatment. We hope the rigorous research, clinical insights, and collective expertise represented in this guideline will help improve outcomes for those affected by this challenging condition.”
KDIGO thanks the Guideline Work Group for their dedication and expertise and the Evidence Review Team from Brown University School of Public Health for their comprehensive work on this guideline.
#lupus #lupusnephritis
Alessandra Ida Celia retweeted
Another Great Rheumatology Roundup (#ACR23) w/ Drs. Kavanaugh & Cush. Abstr:
0025 Cannibinoids & pain
1584 TMP/SMX in GPA
0607 CAR-T cell
1583 SMART
LB07 Arctic Rewind
2480 RA Flare Cutpoints
2548 Uveitis BKZ
2427 PR3+ LN
0445 TCZ biosimilars
1008 ED
L03 VEXAS
1269 3 S Rule
Alessandra Ida Celia retweeted
Urinary biomarkers precede loss of kidney function for lupus nephritis
In Abstract 0850, Dr. Andrea Fava from Johns Hopkins presents research on the value of urinary biomarkers as measure of intrarenal inflammation.
bit.ly/3sCWEKM
Alessandra Ida Celia retweeted
Wonderful presentation by @celia_ida on a possibly novel cell type implicated in lupus nephritis #ACR23 #ACRBest
A#2427 #ACR23 @RheumNow
PR3+ cell abundance higher in prolif LN, more than membranous. Mostly in tuberulointerstitium
Density of PR3+ higher in glomueruli of prolif LN
Correlates with activity, not chronicity
Urinary PR3 predict renal fxn loss at 3y
@jhrheumatology @andreafava
Alessandra Ida Celia retweeted
Great work on LN! #SLE
20-plex serial immunohistochemistry on class Ⅳ LN kidney biopsy @celia_ida
🖊️IL-16+ cells ⬆️ in the tubulointerstitium.
#ACR23 #ACRambassador @ACRheum
Honoured to receive this award! Huge thanks to @LupusAcademy for the opportunity and gratitude to my mentor @andreafava for guiding me every step of the journey! 🙏🏻#grateful #AwardWinning
Congratulations to the Poster Oral Presenters. The reviewers praised all of them, with the final prize going to Alessandra Ida Celia #lupus2023
Alessandra Ida Celia retweeted
💫#MakeLupusVisible! Be part of #WorldLupusDay by joining the conversation on all kind of channels!
🟣Wear your favourite purple items today.
🟣Share Lupus facts on social media.
🟣Participate in the World Lupus Day social media campaign.
#EULAR #Lupus #WorldLupusDay2023
Alessandra Ida Celia retweeted
Thanks for being an amazing inspiration @SelenaGomez – and raising your voice about kidney-related lupus. Working together we’ve made great strides, but the LRA remains steadfast on finding new and better treatments for our community. We salute you & all #lupusnephritis warriors.
Alessandra Ida Celia retweeted
Glomerulonephritis: immunopathogenesis and immunotherapy dlvr.it/Sgmj79
Alessandra Ida Celia retweeted
We are proud of our #EMEUNETtop10abstracts presenters, who did a great job at #ACR22
Want to know more about them? You can find all presenters and abstracts on our website
Read more 👉 emeunet.eular.org/top10_abst…
#EULAR #eularEMEUNET #rheumatology #rheumatologist
Alessandra Ida Celia retweeted
📢 Do not miss!
Alessandra Ida Celia: Proteomic analysis of histological lesions in #Lupus nephritis identifies an inflammatory signature of fibrous crescents
📆 Sunday, 13 November at 9:00
SLE–etiology and pathogenesis
#eularemeunet #EMEUNETtop10abstracts #ACR22
Alessandra Ida Celia retweeted
Neutrophil-derived Ro52 isoforms are targeted by pathogenic autoantibodies in SLE: buff.ly/3VuCv2T
@Eduardo95668787 @Merrlin_p @celia_ida @HopkinsMedicine
#Immunology
Alessandra Ida Celia retweeted
🎉Congratulations to the winners of the #EMEUNETtop10abstracts at #ACR22
Lisa Christ, Alessandra Ida Celia , Shinji Izuka, Cristiana Sieiro Santos, Beatriz Samões, Fabian Proft, Marc Scherlinger, Sarah Dyball, Caoilfhionn Connolly and Julius Lindblom
#RheumTwitter #eularEMEUNET
Alessandra Ida Celia retweeted
🚨 Today #Anifrolumab has been approved in the European Union 🇪🇺 as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic #lupus erythematosus (#SLE), despite receiving standard therapy. 👍
astrazeneca.com/media-centre…
Congratulations! @andreafava
IL-16 is linked to lupus nephritis activity: a novel biomarker and potential therapeutic target discovered by the Accelerating Medicines Partnership! doi.org/10.1002/art.42023
@soumya_boston @Deepakarao @HopkinsMedNews @jhrheumatology @RheumNow @NIH_NIAMS @LupusOrg @LupusResearch
Alessandra Ida Celia retweeted
#OctoberIssue | Most rheumatic and musculoskeletal diseases fall along a spectrum of disorders from #autoinflammatory diseases to #autoimmune diseases, with ‘mixed-pattern’ diseases having features of both.
Find out more in our #Review go.nature.com/3hYvrtg









































